Dose-ranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin.

Add to Collection

2015 Jun Others NB Amin, X Wang, SM Jain, DS Lee… - Diabetes, Obesity …, 2015 - Wiley Online Library 105

Full Author : ['Amin, N B', 'Wang, X', 'Jain, S M', 'Lee, D S', 'Nucci, G', 'Rusnak, J M']
Journal Title : Diabetes, obesity & metabolism
Chapter : Section3
Journal Year : 2015
Cited by : 75.0

AIM: To investigate the efficacy and safety of ertugliflozin, in a phase II dose-ranging study, in patients with type 2 diabetes mellitus (T2DM) inadequately controlled on metformin. METHODS: A total of 328 patients [mean T2DM duration, 6.3 years; mean gl..... Read More

Keywords : ["sodiumglucose cotransporter inhibitor", "type diabetes", "safety study", "doserange efficacy", "patient", "metformin", "ertugliflozin", "background"]
PubMed Link : https://dom-pubs.onlinelibrary.wiley.com/doi/abs/10.1111/dom.12460
Google Scholar Link : https://scholar.google.com/scholar?cites=3868441090792707496&as_sdt=5,49&sciodt=0,49&hl=en&num=20

Have a Question?

Dose-ranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin.